The price adjustment policy for essential medicines list was postponed until next year

It is reported that the "new drug price policy", which has always been concerned about by the public, is expected to be postponed to next year. This is at least two months later than originally scheduled for the end of October. As early as mid-October, the reporter learned from the authoritative department that the basic medicine announced in late October announced that the price reduction plan had been suspended. Earlier there were rumors that the price adjustment of the basic drug list may be introduced in late October, and the general drug price will drop by 10-20%. In fact, the State Development and Reform Commission has carried out a special investigation on the prices of new medicines that have entered the National Health Insurance Catalogue and some of the medicines that have been stipulated for the maximum retail price limit in September (involving more than 900 manufacturing enterprises and nearly 900 varieties). After the investigation work, In the process of soliciting opinions from enterprises, some companies have different opinions, which leads to delay in the release of drug price adjustment documents. According to Song Ruilin, executive president of the China Pharmaceutical Industry Research and Development Promotion Association, the investigation found that certain places were trapped in the "low price is the move" in the centralized bidding for essential drugs. Some small businesses take advantage of it, blindly lower prices, and even lower than the usual pharmaceutical costs. On the surface, the illusion that the essential drugs have a huge price reduction space misleads the decision-making department. In addition, according to informed sources, in the future, the country's adjustment of the prices of base medicines will not simply be price cuts, and prices for medicines that are higher than the market price will have room for price cuts, while the prices of medicines with lower market prices will not drop. The price of some exclusive varieties will also increase.

Since October, the new policy of price adjustment has become a "long-lasting boots" on the market: Once it is landed, it will have an impact on the profitability of pharmaceutical companies, and it will also make the performance of the pharmaceutical sector unsatisfactory since October. According to the latest statistics from the Wonderware system, the entire pharmaceutical sector in October showed an outflow of funds, with a cumulative net outflow of 9.09 billion yuan. Among them, Zixin Pharmaceutical ranked first in the pharmaceutical sector with an increase of 39.72%; Huahai Pharmaceutical ranked first with a decrease of 16.62%. In this regard, industry sources said that the delay in the price adjustment policy introduced next year will not cause major changes to the pharmaceutical market this year. According to Lin Jianning, director of the Southern Food and Economic Research Institute of the State Food and Drug Administration, the total output value of China's pharmaceutical industry will reach 125.6 billion yuan in 2010, up 25% year-on-year. In 2010, the pharmaceutical market in China will reach 755.6 billion yuan, a year-on-year increase of 22%; in 2011, China will be expected to become the third largest pharmaceutical market in the world.